Scleral Allograft-Reinforced Cyclodialysis Combined with Phacoemulsification or Performed as a Standalone Procedure: 24-Month Outcomes from the Multicenter CREST Study
- 1New York Eye and Ear of Mount Sinai, New York, NY, USA
Abstract
Introduction: Acellular scleral allograft-reinforced cyclodialysis is a bio-interventional surgery (BIOS) to lower intraocular pressure (IOP). We report 2-year efficacy and safety outcomes when the procedure is performed in combination with phacoemulsification and as a standalone procedure in eyes with open-angle glaucoma. Methods: Analysis of the multicenter CREST real-world evidence study of eyes undergoing allograft-reinforced cyclodialysis with AlloFlo Uveo (Iantrek, Inc., White Plains, NY; NCT05506423). Eyes attending the Month-24 visit were analyzed: 176 eyes undergoing phaco-combined surgery (Cohort 1) and 32 standalone eyes (Cohort 2). Values recorded after secondary procedures censored. Cohort 1 only was stratified by low, moderate, or high baseline IOP ([≤] 15, 16-20, [≥] 21 mmHg). Results: A total of 176 eyes in Cohort 1 and 32 in Cohort 2 were analyzed. In Cohort 1, IOP decreased 3.1 mmHg at Month 24 from a baseline of 18.0 (-12.5%; p < 0.001), and medications decreased 0.5 from 1.5 (p < 0.001); medication-free eyes rose from 22.9% to 46.4% (p < 0.001). IOP changes in the low, moderate, and high baseline tiers were +0.9 (+7.8%), -3.0 (-16.3%), and -9.2 (-36.1%) mmHg; medication changes were -0.8, -0.6, and +0.1. In Cohort 2, IOP decreased 6.4 mmHg from 20.0 (-27.1%; p < 0.001), and medications decreased 1.2 from 2.8 (p = 0.004); medication-free eyes rose from 4.3% to 30.4% (p = 0.031). Secondary IOP-lowering procedures were performed in 5.1% of Cohort 1 eyes and 28.1% of Cohort 2. Kaplan-Meier freedom from reoperation was 98.9% and 84.4%. No eye developed clinically significant hypotony or choroidal effusion, and there were no allograft-related vision-threatening adverse events. Conclusion: Allograft-reinforced cyclodialysis effectively lowered IOP and medication use through 24 months.
Related
- Standalone Middle Meningeal Artery Embolization Versus Surgical Evacuation for Nontraumatic Subdural Hematoma: A Propensity-Matched Multicenter Real-World Study
- A multicenter prospective validation cohort does not support the use of kidney/psoas [¹⁸F]FDG uptake in the diagnosis of kidney allograft subclinical rejection
- Aspiration-line pressure stability in Venturi and peristaltic pump configurations during phacoemulsification: an in vitro study
- Unilateral ‘cheetah-like’ endotheliopathy: A rare endothelial phenotype regressing after phacoemulsification
- Balanced versus hybrid phacoemulsification tips in grade 3 nuclear cataracts: a prospective randomized clinical study
BibTeX
@misc{weinreb2026scleral,
title = {{Scleral Allograft-Reinforced Cyclodialysis Combined with Phacoemulsification or Performed as a Standalone Procedure: 24-Month Outcomes from the Multicenter CREST Study}},
author = {R. N. Weinreb and L. Provencher and A. S. Huang and A. Yadgarov and M. Rouse and B. Francis and T. Ianchulev and R. Chang},
howpublished = {medRxiv},
year = {2026},
month = nov,
doi = {10.64898/2026.11.02.26367111},
url = {https://www.medrxiv.org/content/10.64898/2026.11.02.26367111v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Scleral Allograft-Reinforced Cyclodialysis Combined with Phacoemulsification or Performed as a Standalone Procedure: 24-Month Outcomes from the Multicenter CREST Study
AU - R. N. Weinreb
AU - L. Provencher
AU - A. S. Huang
AU - A. Yadgarov
AU - M. Rouse
AU - B. Francis
AU - T. Ianchulev
AU - R. Chang
PY - 2026
DA - 2026/11/02
PB - medRxiv
DO - 10.64898/2026.11.02.26367111
UR - https://www.medrxiv.org/content/10.64898/2026.11.02.26367111v1
AB - Introduction: Acellular scleral allograft-reinforced cyclodialysis is a bio-interventional surgery (BIOS) to lower intraocular pressure (IOP). We report 2-year efficacy and safety outcomes when the procedure is performed in combination with phacoemulsification and as a standalone procedure in eyes with open-angle glaucoma. Methods: Analysis of the multicenter CREST real-world evidence study of eyes undergoing allograft-reinforced cyclodialysis with AlloFlo Uveo (Iantrek, Inc., White Plains, NY; NCT05506423). Eyes attending the Month-24 visit were analyzed: 176 eyes undergoing phaco-combined surgery (Cohort 1) and 32 standalone eyes (Cohort 2). Values recorded after secondary procedures censored. Cohort 1 only was stratified by low, moderate, or high baseline IOP ([≤] 15, 16-20, [≥] 21 mmHg). Results: A total of 176 eyes in Cohort 1 and 32 in Cohort 2 were analyzed. In Cohort 1, IOP decreased 3.1 mmHg at Month 24 from a baseline of 18.0 (-12.5%; p < 0.001), and medications decreased 0.5 from 1.5 (p < 0.001); medication-free eyes rose from 22.9% to 46.4% (p < 0.001). IOP changes in the low, moderate, and high baseline tiers were +0.9 (+7.8%), -3.0 (-16.3%), and -9.2 (-36.1%) mmHg; medication changes were -0.8, -0.6, and +0.1. In Cohort 2, IOP decreased 6.4 mmHg from 20.0 (-27.1%; p < 0.001), and medications decreased 1.2 from 2.8 (p = 0.004); medication-free eyes rose from 4.3% to 30.4% (p = 0.031). Secondary IOP-lowering procedures were performed in 5.1% of Cohort 1 eyes and 28.1% of Cohort 2. Kaplan-Meier freedom from reoperation was 98.9% and 84.4%. No eye developed clinically significant hypotony or choroidal effusion, and there were no allograft-related vision-threatening adverse events. Conclusion: Allograft-reinforced cyclodialysis effectively lowered IOP and medication use through 24 months.
ER -